Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary

• DOI: 10.1371/journal.pone.0218071
• Publication Date: 2019-06-13T17:36:52Z
• Authors: P. Takács; P. Czobor; L. Fehér; J. Gimesi-Országh; P. Fadgyas-Freyler; M. Bacskai; P. Rakonczai; A. Borsi; R. Hegyi; T. Németh; J. Sermon; I. Bitter
• Keywords: Discontinuation; Paliperidone; Paliperidone Palmitate

Background Schizophrenia is a severe condition that affects approximately 1% of the population. Certain elements antipsychotic treatment can only be examined in large population, thus need for population-based real-world analyses has been increasing. Patients and methods Hungarian National Health Fund database includes all healthcare data population Hungary. All patients diagnosed with schizophrenia between 01.01.2006 31.12.2015 were included study. We analyzed newly initiated second-generation during inclusion period (01.01.2012–31.12.2013). followed 2 years. All-cause discontinuation served as primary outcome long-acting injectable treatments further investigated stratified based on their previous treatment. Results 106,624 had diagnosis study period. 12,232 met criteria initiating The proportion still after 1 year oral varied 17% (oral risperidone) 31% olanzapine) while analogous long acting injectables 32% (risperidone acting) 64% (paliperidone one monthly). 2-year similarly favor long-actings. Median time to group 57 days (clozapine) 121 (olanzapine). median long-actings was significantly longer: 176 287 days; case paliperidone acting, not reached observation receiving switched from another remained longer than those orals. Conclusion Our results indicate superiority second generation antipsychotics regard rates periods persistence assigned medication.